ZICAM AND SARS CoV WARS by Dr. Charles B. Hensley

Born in McAlester, Oklahoma, Charles Benjamin Hensley grows up in Virginia before returning to Oklahoma and eventually pursuing higher education. After playing college football, he studies marine biology in California, where he works with shark biologist Don Nelson. His scientific career later takes him to the University of Southern California, where he completes predoctoral and postdoctoral research and enters the pharmaceutical world. But professional ambition does not protect him from personal upheaval. A divorce separates him from his first wife, Linda, and their four daughters, leaving Charles to navigate loss while searching for a new direction.

By the late 1990s, Charles is teaching at Cleveland Chiropractic College and dreaming of starting a biotechnology company. His unconventional style makes him popular with students but puts him at odds with Dean Dr. Kahn. After a wild karaoke party and a tense confrontation, Charles decides to leave the college. When a student, Rob Davidson, approaches him with the possibility of investment, Charles initially dismisses him. But Rob persists, and Charles eventually agrees to meet an investor, Larry Kaye.

The first attempt at building a company is chaotic. Larry offers makeshift lab space inside his supplement store, and Charles and Rob struggle to work amid cramped conditions, limited resources, and disagreements over the company’s direction. Charles is convinced zinc could help address the common cold, but an early product effort fails to meet expectations. He refuses to abandon the idea, however, insisting the science may be sound even if the formulation is not yet right. As the partners clash over money and strategy, Charles and Rob search for new investors and corporate allies.

At USC, Charles works with researcher Ernesto Barron to investigate how ionic zinc might affect cold viruses in the nose. Their experiments and computer modeling give Charles confidence that they have identified a mechanism worth pursuing. He names the product Zicam. The company faces setbacks, investor disputes, and a potentially damaging licensing arrangement with a large corporation. Charles suspects the licensing partner may be delaying the product’s progress and pushing its own interests. He and Rob terminate the agreement and decide to launch Zicam themselves.

After repeated rejections, they form an alliance with GumTech International, which agrees to establish a joint venture called GelTech. The partnership gives them a route to fund research, pursue patents, and prepare a formal clinical study. Charles resists becoming a polished corporate spokesperson, but Eriko—someone from his past who believes in him—encourages him to accept the responsibilities that come with leading the company. With the team working around the clock, Zicam secures commitments from major retailers and prepares for a national launch.

The launch is a gamble. GelTech races to finish the research, prepare media materials, and coordinate a high-profile announcement. A major pharmaceutical company warns that the public may not believe the claims, while the team struggles to meet deadlines. Their findings are accepted for publication, and a reporter at *USA Today* ultimately agrees to run the story despite outside pressure. When the paper appears on the front page, the team celebrates—but the next day’s response remains uncertain.

Charles leaves the group to drive along the Pacific Coast Highway, trying to escape the tension. A television report about Zicam catches Rob’s attention at a bar. He calls Charles with the news: Zicam is everywhere, and the public is responding. Charles pulls over, overwhelmed. He calls Eriko, then sits by the ocean, recognizing that the long, difficult journey has brought the company to a defining moment.

Years later, Charles is working with Ernesto at PRB Pharmaceuticals on a new botanical antiviral formula. In 2003, Benjamin Li calls from China with an urgent concern: a dangerous new virus is appearing, and doctors may need help. Charles initially hesitates; the formula is unfinished, and little is known about the disease. Soon, alarming reports about SARS emerge from China, Hong Kong, and Taiwan. Charles worries about friends and colleagues caught in the outbreak.

Krystal Jang, a Taiwanese feng shui master, tells Charles that people in Taiwan want him to come and explore whether his research might help. Charles is reluctant to promise anything, but the worsening crisis weighs on him. He turns to the scientific literature and works through the night, developing a theoretical approach that he believes may have broader antiviral potential. Exhausted, he wakes to a room full of notes and slowly reconstructs what he has written.

Charles brings his ideas to Ernesto, asking him to judge whether the theory is promising. Ernesto is impressed but cautions that they cannot test directly against SARS in their laboratory. He proposes beginning with a related animal coronavirus while they seek access to appropriate facilities. Charles pushes for rapid testing, but Ernesto insists safety and scientific rigor must come first.

The story follows Charles through ambition, failure, reinvention, and high-stakes decisions. His rise with Zicam and his later involvement in the SARS crisis are presented as parts of one larger struggle: the attempt to turn bold scientific ideas into products that can reach people in need. Along the way, Charles must confront the limits of his confidence, the responsibilities of leadership, and the difference between a promising hypothesis and a proven treatment.